PRESS RELEASE published on 07/09/2026 at 08:00, 2 months 15 days ago Pentixapharm Receives FDA Fast Track Designation for Phase 3 Diagnostic Candidate [⁶⁸Ga]Ga-PentixaFor in Primary Aldosteronism Pentixapharm Holding AG granted FDA Fast Track designation for [⁶⁸Ga]Ga-PentixaFor diagnostic candidate in primary aldosteronism. Fast Track streamlines regulatory process & interaction with FDA FDA Fast Track Pentixapharm Primary Aldosteronism Regulatory Milestone Diagnostic Candidate
BRIEF published on 07/09/2026 at 07:08, 2 months 15 days ago Pentixapharm Holding AG obtient la procédure accélérée de la FDA pour son candidat diagnostic Procédure Accélérée De La FDA Aldostéronisme Primaire Examen Réglementaire Étude PANDA [68Ga]Ga-PentixaPour
BRIEF published on 07/09/2026 at 07:08, 2 months 15 days ago Pentixapharm Holding AG Secures FDA Fast Track for Diagnostic Candidate FDA Fast Track Primary Aldosteronism Regulatory Review PANDA Study [68Ga]Ga-PentixaFor
PRESS RELEASE published on 07/09/2026 at 07:03, 2 months 15 days ago EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm Receives FDA Fast Track Designation for [⁶⁸Ga]Ga-PentixaFor for the Subtyping of Primary Aldosteronism Pentixapharm Holding AG receives FDA Fast Track designation for [⁶⁸Ga]Ga-PentixaFor for subtyping of Primary Aldosteronism, allowing more efficient regulatory review process FDA Fast Track Primary Aldosteronism Pentixapharm Holding AG [68Ga]Ga-PentixaFor Subtyping
BRIEF published on 07/01/2026 at 15:32, 2 months 23 days ago Pentixapharm lance une levée de fonds pour financer la phase 3 de son essai clinique PANDA et sa croissance aux États-Unis. Augmentation De Capital Pentixapharm Émission De Droits Expansion Américaine PANDA Phase 3
BRIEF published on 07/01/2026 at 15:32, 2 months 23 days ago Pentixapharm Initiates Capital Expansion for PANDA Phase 3 and U.S. Growth Capital Increase Rights Issue U.S. Expansion Pentixapharm PANDA Phase 3
PRESS RELEASE published on 07/01/2026 at 15:27, 2 months 23 days ago Pentixapharm Launches Rights Issue to Fund PANDA Phase 3 and U.S. Expansion Pentixapharm launches rights issue to fund PANDA Phase 3 study and U.S. expansion, major shareholder commits to full exercise of subscription rights Capital Increase Rights Issue U.S. Expansion Pentixapharm PANDA Phase 3
BRIEF published on 07/01/2026 at 12:10, 2 months 23 days ago Pentixapharm Holding AG Plans Rights Issue to Raise EUR 20.4 Million Capital Increase Rights Issue Subscription Price PANDA Phase 3 Study Eckert Wagniskapital
BRIEF published on 07/01/2026 at 12:10, 2 months 23 days ago Pentixapharm Holding AG prévoit une augmentation de capital par émission de droits pour lever 20,4 millions d'euros. Augmentation De Capital Émission De Droits Prix De L'abonnement Eckert Wagniskapital Étude PANDA De Phase 3
PRESS RELEASE published on 07/01/2026 at 12:05, 2 months 23 days ago EQS-Adhoc: Pentixapharm Holding AG: Resolves on Rights Issue with an Offering Volume of up to Appr. EUR 20.4 Million; Major Shareholder Eckert Wagniskapital Commits to Fully Exercise Its Subscription Rights Pentixapharm Holding AG resolves on rights issue worth up to EUR 20.4 million; Eckert Wagniskapital to fully exercise subscription rights for new shares, supporting corporate development and PANDA Phase 3 study Rights Issue Subscription Rights Pentixapharm Holding AG PANDA Phase 3 Study Eckert Wagniskapital
Published on 09/24/2026 at 22:01, 24 minutes ago Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 14:55, 7 hours 30 minutes ago Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements
Published on 09/24/2026 at 14:30, 7 hours 55 minutes ago Solitario Resources CEO to Present at the 38th Annual Mining Forum Americas 2026 Conference
Published on 09/24/2026 at 14:00, 8 hours 25 minutes ago Horizon Aircraft to Report First Quarter 2027 Results and Provide a Business Update on October 9, 2026
Published on 09/24/2026 at 20:29, 1 hour 56 minutes ago EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 3 hours 25 minutes ago HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:40, 3 hours 44 minutes ago EQS-Adhoc: Brockhaus Technologies AG launches public share buyback offer of approx. €90 million for up to 3,592,000 shares
Published on 09/24/2026 at 18:15, 4 hours 10 minutes ago Epanko Value Engineering Identifies 20% Production Increase
Published on 09/24/2026 at 18:05, 4 hours 19 minutes ago DCK Tools Showcases Expanded Outdoor Power Equipment Lineup at Salonvert 2026
Published on 09/24/2026 at 18:31, 3 hours 53 minutes ago LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:00, 4 hours 25 minutes ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 4 hours 25 minutes ago GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026